LIPOSOMAL CURCUMIN
500MG CAPSULES

INFLUENCE & POTENTIAL ROLES IN CANCER CARE & SUPPORT

Microscopic cells iconCircular blue medical icon with blue, purple and red microscopic cells.

APOPTOSIS INDUCTION

Helps activate programmed cell-death pathways, promoting the removal of abnormal cells.

Blood vessel network iconCircular medical icon showing a branching red blood vessel network.

ANGIOGENESIS INHIBITION / VEGF MODULATION

Reduce VEGF-related signalling involved in the formation of new blood vessels that support tumour growth.

Purple cell iconCircular medical icon showing a large purple cell with nucleus and smaller cells.

ANTI-INFLAMMATORY ACTION / NF-κB MODULATION

Modulate NF-κB and other inflammatory pathways associated with tumour-promoting inflammation.

IV infusion bag iconTransparent medical icon showing an IV infusion bag containing amber fluid and a curved tube.

CHEMOSENSITIZATION

Increase the sensitivity of some cancer cells to chemotherapy.

Gut microbiome iconClean vector illustration of the intestines with a blue inset showing beneficial gut bacteria.

GUT MICROBIOME SUPPORT

Interact with gut microbiota and support microbial balance; clinical significance is under investigation.

Blue medical shield against virusesClean vector illustration of a blue medical shield and white cross protecting against two green virus cells.

MODULATES IMMUNE RESPONSE

Enhance T-cell activity and modulate immune signalling, reducing tumour immune evasion.

Green cellular protection shieldClean vector illustration of a layered green shield with a white segmented protective-cell emblem.

ANTIOXIDANT & CYTOPROTECTIVE

Protect healthy cells and tissues from oxidative damage and treatment-related stress.

Healthy life and heart iconClean vector illustration of a green person raising both arms with a red heart on the chest.

IMPROVES QUALITY OF LIFE

Support energy, appetite and overall well-being during cancer care.

Cell cycle phases icon

PROLIFERATION ARREST & CELL-CYCLE REGULATION

Interfere with cell-cycle signalling, slowing uncontrolled cancer cell multiplication.

Medical cell cluster iconClean vector illustration of a red cell cluster with purple nuclei and surrounding cells.

METASTASIS SUPPRESSION

Influence pathways involved in cancer-cell invasion, migration, adhesion and metastatic spread.

Immune cell interaction iconVector illustration of blue immune cells with purple nuclei interacting with green spiked cells.

IMMUNE MODULATION

Influence macrophage activity, T-cell responses and regulatory immune pathways in the tumour microenvironment.

RADIATION SENSITIZATION

Enhance the effects of radiation by modifying cellular stress and survival pathways.

ROS oxidative balance iconVector illustration of a red balance scale with ROS label and red blood cells.ROS

OXIDATIVE STRESS REDUCTION / ROS SCAVENGING

Curcumin has antioxidant activity and may help regulate excessive ROS and oxidative stress.

Medical protection shield iconVector illustration of a red medical shield protecting against blue pathogen cells.

REDUCES INFLAMMATION

Control cytokine storms and inflammatory responses, supporting recovery during cancer care.

Target and arrow iconClean vector illustration of a blue and red target with an arrow in the bullseye.

ENHANCES TREATMENT EFFICACY

Investigational evidence suggests it may improve response to immunotherapy and chemotherapy.

Clasped hands support iconClean vector illustration of two hands clasped together in support and unity.

ADJUVANT / SUPPORTIVE TREATMENT

A supportive component alongside standard cancer treatment under medical supervision.

LIPOSOMAL CURCUMIN IN SOLID TUMOURS

BRAIN TUMORS (HIGH-GRADE GLIOMAS)

HOW IT WORKS / ACTION / MECHANISM

  • Radiation damages tumor-cell DNA and induces apoptosis
  • Temozolomide alkylates DNA, inhibiting tumor-cell replication
  • Enhances DNA damage and cell-cycle arrest
  • May help reduce tumor-cell proliferation and survival

CURSOMAL USAGE:500 mg once daily as an adjunct to radiation and temozolomide therapy in patients with newly diagnosed high-grade gliomas, under oncologist supervision.

Journal of Clinical Oncology®

AMERICAN SOCIETY
OF CLINICAL ONCOLOGY

ASCO Publications

Meeting Abstract: 2026 ASCO Annual Meeting
Nervous System Tumors | May 27, 2026

LIPOSOMAL CURCUMIN IN COMBINATION WITH STANDARD RADIATION AND TEMOZOLOMIDE:

Phase I/II study of liposomal curcumin in combination with standard radiation and temozolomide in patients with newly diagnosed high-grade gliomas.

File-pdf

CERVICAL CANCER

HOW IT WORKS / ACTION / MECHANISM

  • Inhibits HPV oncogene expression (E6/E7)
  • induces apoptosis and cell-cycle arrest
  • inhibits NF-κB, PI3K/AKT and VEGF
  • enhances radiosensitivity.

CURSOMAL USAGE:500MG 1-2 TIMES DIALY WITH CHEMO / RADIATION THERAPY

COLORECTAL CANCER (CRC)

HOW IT WORKS / ACTION / MECHANISM

  • Inhibits Wnt/β-catenin, NF-κB and COX-2
  • induces apoptosis and G1/S cell-cycle arrest
  • reduces angiogenesis and metastasis
  • modulates gut microbiota.

CURSOMAL USAGE: 500 mg 1–2 times daily with chemotherapy (5FU/Oxaliplatin).

ENDOMETRIAL CANCER (DMMR)

HOW IT WORKS / ACTION / MECHANISM

  • Modulates immune microenvironment
  • Inhibits PI3K/AKT/mTOR and NF-κB
  • Induces apoptosis and cell-cycle arrest
  • Enhances response to immunotherapy.

CURSOMAL USAGE:500 mg 1–2 times daily with chemotherapy/radiation therapy.

GASTRIC / GASTRO-ESOPHAGEAL JUNCTION ADENOCARCINOMA

HOW IT WORKS /ACTION / MECHANISM

  • Inhibits NF-κB, COX-2 and β-catenin
  • Induces apoptosis and G2/M cell-cycle arrest
  • Reduces proliferation and angiogenesis
  • Enhances chemosensitivity.

CURSOMAL USAGE:500 mg 1–2 times daily with chemotherapy (5-FU/Platinum), as an adjunct.

HEAD AND NECK CANCER (HNSCC)

HOW IT WORKS /ACTION / MECHANISM

  • Inhibits NF-κB, STAT3 and COX-2
  • induces apoptosis and cell-cycle arrest
  • reduces invasion and angiogenesis
  • enhances radiosensitivity.

CURSOMAL USAGE:500 mg 1–2 times daily with chemotherapy (5-FU/Platinum), as an adjunct.

HEPATOCELLULAR CARCINOMA (HCC)

HOW IT WORKS / ACTION / MECHANISM

  • Inhibits NF-κB, STAT3 and Wnt/β-catenin
  • induces apoptosis and cell-cycle arrest
  • reduces angiogenesis (↓ VEGF
  • decreases metastasis.

CURSOMAL USAGE:500 mg 1–2 times daily with TACE, Sorafenib or immunotherapy.

HODGKIN LYMPHOMA

HOW IT WORKS / ACTION / MECHANISM

  • Induces apoptosis in Reed–Sternberg cells
  • inhibits NF-κB and JAK/STAT signalling
  • modulates immune microenvironment
  • reduces inflammatory cytokines.

CURSOMAL USAGE:500 mg 1–2 times daily as an adjunct to chemotherapy (ABVD regimen).

MELANOMA

HOW IT WORKS / ACTION / MECHANISM

  • Inhibits MAPK/ERK and NF-κB pathways
  • induces apoptosis and autophagy
  • enhances immune response (↑ CD8+ T cells)
  • reduces angiogenesis.

CURSOMAL USAGE:500 mg 1–2 times daily with immunotherapy or BRAF/MEK inhibitors.

Non-Small Cell Lung Cancer (NSCLC)

HOW IT WORKS / ACTION / MECHANISM

  • Inhibits EGFR, PI3K/AKT and NF-κB
  • induces apoptosis and autophagy
  • reduces angiogenesis (↓ VEGF)
  • overcomes drug resistance.

CURSOMAL USAGE:500 mg 1–2 times daily with standard therapy (chemotherapy /targeted therapy).

PANCREATIC CANCER

HOW IT WORKS / ACTION / MECHANISM

  • Inhibits KRAS, NF-κB and Hedgehog signalling
  • induces apoptosis and autophagy
  • reduces desmoplasia, invasion and angiogenesis
  • enhances chemotherapy efficacy

CURSOMAL USAGE:500 mg 1–2 times daily with chemotherapy (Gemcitabine–Paclitaxel).

RENAL CELL CARCINOMA (RCC)

HOW IT WORKS / ACTION / MECHANISM

  • Inhibits VEGF, HIF-1α and mTOR pathways
  • induces apoptosis and G1 cell-cycle arrest
  • reduces angiogenesis and invasion
  • modulates immune response.

CURSOMAL USAGE:500 mg 1–2 times daily with targeted therapy (TKI) or immunotherapy.

THYROID CANCER

HOW IT WORKS / ACTION / MECHANISM

  • Inhibits RET, BRAF/MEK and PI3K/AKT pathways
  • induces apoptosis and inhibits proliferation
  • reduces angiogenesis and invasion
  • may improve RAI sensitivity

CURSOMAL USAGE:500 mg 1–2 times daily with radioactive iodine or targeted therapy.

TRIPLE NEGATIVE BREAST CANCER (TNBC)

HOW IT WORKS / ACTION / MECHANISM

  • Inhibits PI3K/AKT/mTOR, NF-κB and STAT3
  • induces apoptosis and inhibits stemness
  • reduces invasion, EMT and angiogenesis
  • overcomes drug resistance.

CURSOMAL USAGE:500 mg 1–2 times daily with chemotherapy or immunotherapy, as an adjunct.

UROTHELIAL CARCINOMA (UC)

HOW IT WORKS / ACTION / MECHANISM

  • Inhibits STAT3, NF-κB and MMPs
  • induces apoptosis and cell-cycle arrest
  • reduces invasion, migration and angiogenesis
  • enhances chemosensitivity.

CURSOMAL USAGE::500 mg 1–2 times daily with chemotherapy (Gemcitabine/ Cisplatin), as an adjunct.

LIPOSOMAL CURCUMIN IN HEMATOLOGICAL MALIGNANCIES

CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

HOW IT WORKS / ACTION / MECHANISM

  • Induces apoptosis in CLL cells
  • inhibits NF-κB and BCR signalling
  • overcomes microenvironment protection
  • enhances chemosensitivity.

CURSOMAL USAGE:500 mg 1–2 times daily with standard therapy (Venetoclax / Ibrutinib) or as supportive care.

CLASSICAL HODGKIN LYMPHOMA (cHL)

HOW IT WORKS / ACTION / MECHANISM

  • Induces apoptosis in Reed–Sternberg cells
  • inhibits NF-κB, COX-2 and BCL-XL
  • sensitizes tumour cells to rituximab
  • modulates tumour microenvironment.

CURSOMAL USAGE:500 mg 1–2 times daily with R-CHOP or immunochemotherapy regimens.

DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)

HOW IT WORKS / ACTION / MECHANISM

  • Induces apoptosis via mitochondrial pathway
  • inhibits NF-κB and STAT6 signalling
  • reduces inflammatory cytokines (IL-6, IL-13)
  • enhances immune surveillance.

CURSOMAL USAGE:500 mg 1–2 times daily as an adjunct to standard therapy (ABVD regimen) under medical supervision.

FOLLICULAR LYMPHOMA

HOW IT WORKS / ACTION / MECHANISM

  • Inhibits BCL-2, BCL-XL and NF-κB pathways
  • induces cell-cycle arrest (G0/G1 phase)
  • reduces angiogenesis (↓ VEGF)
  • enhances immune-mediated killing.

CURSOMAL USAGE:500 mg 1–2 times daily with standard therapy (Rituximab ± Chemotherapy) as supportive care.

MANTLE CELL LYMPHOMA

HOW IT WORKS / ACTION / MECHANISM

  • Inhibits NF-κB, Cyclin D1 and BCL-2
  • overcomes drug resistance
  • induces apoptosis and autophagy
  • modulates survival signalling pathways.

CURSOMAL USAGE: 500 mg 1–2 times daily with BTK inhibitors (Ibrutinib / Acalabrutinib) or chemotherapy regimens.

MULTIPLE MYELOMA

HOW IT WORKS / ACTION / MECHANISM

  • Inhibits NF-κB, STAT3 and IL-6 signalling
  • induces apoptosis in plasma cells
  • inhibits bone resorption (↓ RANKL)
  • reduces angiogenesis and cytokine storm.

CURSOMAL USAGE500 mg 1–2 times daily with bortezomib, lenalidomide or other myeloma regimens, as an adjunct.

PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA (PMBCL)

HOW IT WORKS / ACTION / MECHANISM

  • Downregulates NF-κB, BCL-2 and MYC
  • promotes apoptosis and cell-cycle arrest
  • reduces PD-L1 expression
  • inhibits PI3K/AKT/mTOR pathway.

CURSOMAL USAGE :500 mg 1–2 times daily along with R-CHOP / DA-EPOCH regimen, as an adjunct.

Scroll to Top